Vertex Pharmaceuticals Incorporated: all 295 studies

Page 1 of 3. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeNot yet recruitingNCT07890909Phase 3
• Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseNot yet recruitingNCT07868926Phase 1
• A Phase 1 Relative Bioavailability Study of a VX-581 Tablet FormulationRecruitingNCT07813039Phase 1
• A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyEnrolling by invitationNCT07807995Phase 3
• Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesRecruitingNCT07792408Phase 1
• A Phase 1, First-in-human Study of VX-433RecruitingNCT07584434Phase 1
• Evaluation of Pain Treatment After Total Knee ArthroplastyRecruitingNCT07538570Phase 4
• A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisRecruitingNCT07501702Phase 2
• Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsRecruitingNCT07437105Phase 1
• Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisRecruitingNCT07283770Phase 1
• Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyRecruitingNCT07231419Phase 3
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)RecruitingNCT07204275Phase 2/3
• A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)RecruitingNCT07159841Phase 2/3
• A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaRecruitingNCT07144163Phase 3
• A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IEnrolling by invitationNCT06926621Phase 2
• An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantRecruitingNCT06832410Phase 3
• An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal HyperplasiaRecruitingNCT06712823Phase 2
• Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyRecruitingNCT06628908Phase 3
• Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyRecruitingNCT06619860Phase 2
• Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and OlderEnrolling by invitationNCT05844449Phase 3
• Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseRecruitingNCT05477563Phase 3
• A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesRecruitingNCT04786262Phase 3
• A Long-term Follow-up Study in Participants Who Received CTX001Enrolling by invitationNCT04208529Phase 3
• Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)CompletedNCT05907291Phase 2Results posted
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedNCT05882357Phase 3Results posted
• A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute PainCompletedNCT05661734Phase 3Results posted
• Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)CompletedNCT05660538Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ GenotypeTerminatedNCT05643495Phase 2Results posted
• Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an AbdominoplastyCompletedNCT05558410Phase 3Results posted
• Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a BunionectomyCompletedNCT05553366Phase 3Results posted
• Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeCompletedNCT05361668Phase 2Results posted
• Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedNCT05274269Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)TerminatedNCT05192382Phase 3Results posted
• A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)CompletedNCT05111145Phase 3Results posted
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del MutationCompletedNCT05076149Phase 3Results posted
• A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an AbdominoplastyCompletedNCT05034952Phase 2Results posted
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)CompletedNCT05033080Phase 3Results posted
• A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a BunionectomyCompletedNCT04977336Phase 2Results posted
• A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedNCT04969224Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of AcromegalyTerminatedNCT04837040Phase 3Results posted
• ALPN-101 (Acazicolcept) in Systemic Lupus ErythematosusCompletedNCT04835441Phase 2Results posted
• A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes MellitusTerminatedNCT04678557Phase 1/2Results posted
• A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedNCT04599465Phase 3Results posted
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedNCT04545515Phase 3Results posted
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCompletedNCT04537793Phase 3Results posted
• Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ GenotypeCompletedNCT04474197Phase 2Results posted
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyCompletedNCT04362761Phase 3Results posted
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesCompletedNCT04353817Phase 3Results posted
• Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental GlomerulosclerosisCompletedNCT04340362Phase 2Results posted
• Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationCompletedNCT04235140Phase 3Results posted
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedNCT04183790Phase 3Results posted
• Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ GenotypeTerminatedNCT04167345Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508delCompletedNCT04105972Phase 3Results posted
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT04058366Phase 3Results posted
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)CompletedNCT04058353Phase 3Results posted
• A Study Evaluating the Long-term Safety of VX-445 Combination TherapyCompletedNCT04043806Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT03912233Phase 2Results posted
• A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCompletedNCT03911713Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)CompletedNCT03792555Phase 2Results posted
• An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)CompletedNCT03789656Phase 2Results posted
• Study of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisCompletedNCT03768089Phase 1/2Results posted
• A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following BunionectomyCompletedNCT03764072Phase 2Results posted
• A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseaseCompletedNCT03745287Phase 2/3Results posted
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCompletedNCT03691779Phase 3Results posted
• Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeTerminatedNCT03633526Phase 3Results posted
• A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedNCT03625466Phase 2Results posted
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508delCompletedNCT03601637Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic FibrosisCompletedNCT03559062Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR MutationCompletedNCT03537651Phase 3Results posted
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT03525574Phase 3Results posted
• A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedNCT03525548Phase 3Results posted
• A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)CompletedNCT03525444Phase 3Results posted
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedNCT03460990Phase 3Results posted
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyTerminatedNCT03447262Phase 3Results posted
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)CompletedNCT03447249Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber NeuropathyCompletedNCT03304522Phase 2Results posted
• A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive MutationCompletedNCT03277196Phase 3Results posted
• A Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisCompletedNCT03227471Phase 1/2Results posted
• A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT03224351Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following BunionectomyCompletedNCT03206749Phase 2Results posted
• A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia UnawarenessCompletedNCT03163511Phase 1/2Results posted
• A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)CompletedNCT03150719Phase 3Results posted
• A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT03125395Phase 3Results posted
• A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR MutationCompletedNCT03068312Phase 3Results posted
• Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR MutationCompletedNCT03061331Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating MutationsTerminatedNCT02971839Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)CompletedNCT02953314Phase 3Results posted
• A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic FibrosisCompletedNCT02951195Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT02951182Phase 2Results posted
• A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCompletedNCT02875366Phase 4Results posted
• A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR MutationTerminatedNCT02823470Phase 4Results posted
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedNCT02797132Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating MutationTerminatedNCT02742519Phase 3Results posted
• A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR MutationCompletedNCT02730208Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR MutationCompletedNCT02725567Phase 3Results posted
• Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord InjuryTerminatedNCT02669849Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationCompletedNCT02565914Phase 3Results posted
• Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With IvacaftorCompletedNCT02544451Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR MutationCompletedNCT02516410Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR MutationCompletedNCT02514473Phase 3Results posted

← Vertex Pharmaceuticals Incorporated overview and focus areas